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INTRODUCTION
Insulin-like growth factor (IGF-1) is a 70 amino acid (7.6 kDa)
cytokine constitutively produced by the liver due to stimulation
by insulin [1] and growth hormone [2]. IGF-1, which exhibits a
high degree of structural homology to proinsulin, acts to lower
glucose levels [3, 4] and suppress insulin production [5].
There are at least six IGF binding proteins (IGFBPs).
IGFBP-3 is the major IGFBP in serum, with more than 90% of
circulating IGF-1 bound in a ternary complex with IGFBP-3
and acid-labile subunit, and only 1% of the total serum IGF-1
normally circulates in free form [4, 5-8]. While IGFBP-3 is
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ABSTRACT. Background: IGF-1 and the major serum IGF-1 binding protein, IGFBP-3, are under
extensive investigation as potential prognostic markers of specific malignancies and vascular diseases.
However, there is conflicting evidence that tobacco smoking may influence systemic concentrations of
IGF-1 and IGFBP-3.
Subjects and methods: Serum concentrations of IGF-1 and IGFBP-3 were measured in 20 smokers and 20
non-smokers, matched for age and gender. Serum concentrations of cotinine, the major metabolite of
nicotine, and ICAM-1, known to exhibit a dose-dependent relationship with cotinine, were also assayed.
Results: There was no difference between the systemic concentrations of IGF-1 or IGFBP-3 found in
smokers and non-smokers (IGF-1: mean [s.d]; 104 [29] vs 101 [24] ng ml-1, respectively; and IGFBP-3: 2562
[522] vs 2447 [570] ng ml-1, respectively). Similarly, there was no correlation between serum cotinine and
IGF-1 or IGFBP-3 concentrations in smokers. Soluble ICAM-1 concentrations were significantly increased
in smokers, compared to non-smokers (mean [s.d]; 258 [60] vs 194 [50] ng ml-1, respectively; p = 0.002).
Conclusions: There was no relationship noted between tobacco smoking and either IGF-1 or IGFBP-3.
These data suggest that smoking would not appear to be a major confounder of the reported clinical asso-
ciations between IGF-1, IGFBP-3, or IGF-1/IGFBP-3 ratios and specific disease entities.
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expressed in many tissues, non-parenchymal liver cells are con-
sidered the primary source of circulating IGFBP-3. IGFBP-3 is
susceptible to cleavage by a variety of proteases, including
cathepsin G [9], neutrophil elastase [9], and metalloproteases
[10, 11]. Proteolytic cleavage of systemic IGFBP-3 would
increase the amount of free IGF-1, and be expected to alter
the systemic IGF-1/IGFBP-3 ratio.
IGF-1 and IGFBP-3 both promote the differentiation of
bone, with systemic levels of IGF-1 and IGFBP-3 positively
associated with bone mass density (12). Indeed, there is
increasing evidence that alterations to the IGF-1/IGFBP axis
are associated with osteoporosis [13-15]. IGF-1 has been
shown to act as a potent mitogen, with anti-apoptotic actions,
on various cancer cells [16], whereas IGFBP-3 may have IGF-
1-independent pro-apoptotic activity [17, 18]. An aetiological
role for IGF-1 and IGFBP-3 in malignancy is supported by
clinical studies that associate high IGF-1 and low IGFBP-3 lev-
els with increased risk of several cancers, such as breast, col-
orectum, and lung cancer [19-21]. Dysregulation of the
IGF/IGFBP system is also thought to influence the develop-
ment of coronary atherosclerosis and other vascular diseases
[22-26].
It should be noted that specific malignancies (including
colorectal, lung and breast cancers), osteoporosis, and vascu-
lar disease are all tobacco-induced and/or - exacerbated dis-
eases. Previous studies have come to conflicting conclusions
on a potential relationship between IGF-1, IGFBP-3 and
smoking status [20, 21, 23, 27-30]. Considering the important
potential of the IGF/IGFBP system as prognostic markers of
malignancy and vascular disease, there is a pressing need to
clarify the relationship between tobacco use and the systemic
load of IGF-1 and the major IGF-1 binding protein, IGFBP-3.
Age and gender have been shown to correlate negatively with
serum IGF-1 and IGFBP-3 concentrations [12, 20, 23, 27, 31].
We have previously shown that circulating concentrations of
soluble intercellular adhesion molecule-1 (sICAM-1; CD54)
are known to be significantly elevated in smokers, in a dose-
dependent manner, making this a suitable positive control
serum marker [32, 33]. Therefore, we examined the circulating
concentrations of IGF-1, IGFBP-3, and soluble ICAM-1 in 20
smokers and 20 non-smokers, matched for age and gender,





Serum was obtained from 20 smokers and 20 non-smokers,
matched for age and gender (12 females in each group) and
stored at -80°C until required. The mean age of the smoking
group was 44.4 [s.d. 6.1] years. The mean age of the non-smok-
ing group was 44.9 [s.d. 6.5] years. Smokers were required to
have smoked ≥ 10 cigarettes daily for ≥ 3 years. Those who
reported to have consumed no cigarettes in the previous 10
years were considered for inclusion in the non-smoking group.
Smoking status was confirmed by serum cotinine analysis
(smokers ≥ 50 ng ml-1 cotinine; non-smokers ≥ 10 ng ml-1 coti-
nine). Exclusion criteria were pregnancy, diabetes, reported
history of hypertension, angina, any inflammatory disease such
as rheumatoid arthritis or eczema, use of antibiotics within the
preceding 2 months, or the current use of anti-inflammatory
medication, including NSAID's. Written, informed consent
was obtained from each subject, following granting of ethical
approval by the local ethics committee.
Measurement of cotinine
Smoking status was confirmed and tobacco smoke expo-
sure quantified by analysis of serum cotinine, by using a capil-
lary column gas-liquid chromatography technique, as previ-
ously described [34]. Cotinine assays were performed blind to
self-reported smoking status. The mean coefficient of varia-
tion (CV) for analysis of cotinine (over the range 1.0 to 1000
ng ml-1) has been determined to be 2.2% [34]. The lower limit
of detection for cotinine in this system is 100 pg ml-1. Smokers
can be reliably differentiated from non-smokers with over 99%
confidence using an optimal cut-off value of >13.7 ng ml-1
serum cotinine [35].
Measurement of IGF-1
IGF-1 concentrations were measured in duplicate by
immunoassay (Quantikine IGF-1 Immunoassay, R&D
Systems, Minneapolis, MN), using Eschericia coli-expressed
recombinant human IGF-1 to generate the standard curve. The
mean intra-assay CV, determined by assaying the IGF-1 con-
centration in three samples in replicates of twenty, is reported
by the manufacturer to be 3.0%. The mean inter-assay CV,
determined by assaying three samples in forty separate assays,
has been determined to be 8.0%. The mean minimal detectable
concentration of IGF-1 in this assay is 0.026 ng ml-1.
Measurement of IGFBP-3
IGFBP-3 concentrations were measured in duplicate by
immunoassay (Quantikine IGFBP-3 Immunoassay, R&D
Systems, Minneapolis, MN), using NSO-expressed recombi-
nant human IGFBP-3 to generate the standard curve. The
mean intra-assay CV, determined by the manufacturer by
assaying the IGFBP-3 concentration in three samples in repli-
cates of twenty, is reported to be 4.0%. The mean inter-assay
CV, determined by assaying three samples in forty separate
assays, has been determined to be 6.6%. The mean minimal
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detectable concentration of IGFBP-3 in this assay is 0.05 ng
ml-1.
Measurement of sICAM-1
Soluble ICAM-1 concentrations were measured by ELISA
(sICAM-1 Parameter Immunoassay, R&D Systems,
Minneapolis, MN) in duplicate, according to the manufactur-
ers instructions, and as previously described [36]. The mean
intra-assay CV, determined by assaying the sICAM-1 concen-
tration in three serum samples in replicates of ten, is reported
to be 4.4%. The mean inter-assay CV, determined by assaying
three serum samples in duplicate in 18 separate assays by four
operators, has been determined to be 7.4%. The reported sen-
sitivity of the ELISA is less than 0.35 ng ml-1.
Statistical analysis
Statistical analysis was carried out using STATA 7.0 soft-
ware (Stata Corp., Texas 77845, USA). Differences between
smoking groups were analyzed using a two-group t-test.
Relationships between variables were assessed using
Spearman correlation.
RESULTS
The smoking status of all subjects was validated by serum coti-
nine analysis. The serum cotinine concentrations (mean [s.d.])
in the smoking and non-smoking groups were 251.8 [89.8] and
0.79 ng ml-1 [0.72] (p < 0.001), respectively.
Serum IGF-1 levels in individual smokers and non-smok-
ers are shown in Figure 1. There was no significant difference
Figure 1. Serum IGF-1 concentrations ng ml-1 in smokers and non-
smokers. The grey circles represent mean serum concentrations.
Figure 2. Serum IGFBP-3 concentrations ng ml-1 in smokers and non-
smokers. The grey circles represent mean serum concentrations.
Figure 3. Serum ICAM-1 concentrations ng ml-1 in smokers and non-
smokers. The grey circles represent mean serum concentrations.
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in IGF-1 concentrations between smokers and non-smokers
(mean [s.d]; 104 [29] and 101 [24] ng ml-1, respectively).
Serum IGFBP-3 concentrations in individual smokers and
non-smokers are presented in Figure 2. No significant differ-
ence in IGFBP-3 concentrations measured between smokers and
non-smokers (mean [s.d]; 2562 [522] and 2447 [570] ng ml-1,
respectively) was observed.
Furthermore, there was no significant difference in circu-
lating IGF-1 : IGFBP-3 ratios between smokers and non-
smokers (mean [s.d]; 0.041 [0.008] and 0.044 [0.017], respec-
tively). Similarly, there was no correlation between serum coti-
nine and IGF-1 (r = -0.005, p = 0.978) or IGFBP-3 (r = 0.079,
p = 0.628) concentrations in smokers.
Systemic sICAM-1 concentrations, as expected [32, 33],
were significantly elevated in smokers, compared to non-
smokers (mean [s.d]; 258 [60] and 194 [50] ng ml-1, respective-
ly; p = 0.002), as shown in Figure 3.
DISCUSSION
Previous studies that have addressed the possibility of a direct
relationship between tobacco smoking and the systemic load
of IGF-1 and/or IGFBP-3 have been inconsistent in their con-
clusions. Probst-Hensch et al. [29] observed an increase in
IGF-1 concentration in smokers, correlating with the number
of cigarettes consumed daily, but no difference in circulating
IGFBP-3 concentrations between smokers and non-smokers.
Kaklamani et al [27] also reported that IGF-1 concentrations
are higher in smokers, and positively associated with an index
of cumulative smoke exposure (pack-years).
Elsewhere in the medical literature, a negative relationship
between IGF-1 and the amount of tobacco smoked has been
reported, in men only [31]. In another relevant study, Coutant
et al [37] showed that IGF-1 was reduced in cord blood of
neonates from smoking mothers compared to neonates from
non-smoking mothers, and that this reduction was consistent
with their lower birth weight percentile. Others have indicated
that circulating IGF-1 levels may be lowered in smokers, com-
pared to non-smokers [23]. Others have found a minimal or no
relationship between tobacco smoking and IGF-1 concentra-
tions [19, 20, 28].
Recently, Renehan et al [30] recognized that both tobacco
smoking and changes in the IGF/IGFBP system have been
implicated as risk factors for common epithelial cancers.
These authors, therefore, examined the relationship between
cigarette smoke exposure and serum IGF-1, and IGFBP-3 lev-
els. No significant difference in mean serum IGF-1 between
smokers and non-smokers was observed. Mean IGFBP-3 con-
centrations, on the other hand, were significantly lower in
smokers. These results are in agreement with a previous study
that reported serum levels of IGFBP-3 to be independently
and negatively associated with the number of cigarettes
smoked per day or pack-year history of smoking [27].
However, smoking status in the majority of previous studies
has been determined by questionnaire, which is known to be
unreliable [38]. Furthermore, subjects were often not matched
for gender and / or age, both known to influence systemic IGF-
1 and IGFBP-3 concentrations.
Thus, with respect to the relationship between tobacco use
and IGF-1/IGFBP-3 ratios, the present study is an improve-
ment on previous study designs. Smoking subjects have been
matched for age and gender with non-smokers, smoking status
validated biochemically, and tobacco smoke exposure quanti-
fied by serum cotinine analysis. Furthermore, all subjects in
the present study were healthy, with no known confounding
disease or condition that may influence IGF-1 or IGFBP-3
concentrations.
Unlike ICAM-1 (Figure 3), no relationship between tobac-
co smoking and IGF-1 (Figure 1) or IGFBP-3 (Figure 2) was
observed. Therefore, tobacco smoking would not appear to be
a major confounder of the reported clinical associations
between IGF-1, IGFBP-3, or IGF-1/IGFBP-3 ratios and spe-
cific disease entities, including certain malignancies and vascu-
lar disease.
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